利妥昔单抗注射液联合GDP化疗方案对非霍奇金淋巴瘤患者疗效及免疫功能的影响(1)
[摘要] 目的 探討利妥昔单抗注射液联合GDP化疗方案对非霍奇金淋巴瘤(NHL)患者疗效及免疫功能的影响。方法 选取2014年5月～2017年12月江苏省南京市泰康仙林鼓楼医院收治的93例NHL患者为研究对象。根据随机数字表法将患者分为对照组(n = 46)和研究组(n = 47)，对照组患者给予GDP化疗方案治疗，研究组在此基础上联合使用利妥昔单抗注射液。比较两组患者治疗后临床效果、治疗前后免疫功能指标[免疫球蛋白(Ig)A、IgM、IgG以及体液补体C3、C4]、肿瘤标志物[胸腺嘧啶脱氧核甘激酶(TK-1)、血管内皮生长因子(VEGF)]，观察两组患者治疗期间不良反应发生情况。 结果 研究组患者治疗后临床总有效率明显高于对照组(P < 0.05)。两组患者治疗后IgA、IgM、IgG、C3、C4均较治疗前降低，且研究组C3、C4低于对照组，差异有统计学意义(P < 0.05)；两组治疗后IgA、IgM、IgG比较，差异无统计学意义(P > 0.05)。两组患者治疗后TK-1、VEGF均较治疗前降低，且研究组低于对照组，差异有统计学意义(P < 0.05)。两组患者治疗期间不良反应总发生率比较，差异无统计学意义(P > 0.05)。 结论 利妥昔单抗注射液联合GDP化疗方案治疗NHL，效果确切，可有效保护患者免疫功能，显著下调血清TK-1、VEGF水平，且不增加不良反应发生率，具有一定的临床应用价值。
[关键词] 利妥昔单抗；GDP化疗；非霍奇金淋巴瘤；免疫功能
[中图分类号] R733 [文献标识码] A [文章编号] 1673-7210(2018)12(b)-0098-04
[Abstract] Objective To explore the effect of Rituximab Injection combined with GDP chemotherapy on the efficacy and immune function of patients with non Hodgkin lymphoma (NHL). Methods Ninety-three NHL patients admitted to Taikang Xianlin Drum Tower Hospital of Nanjing City in Jiangsu Province from May 2014 to December 2017 were selected as the research subjects. The patients were divided into control group (n = 46) and study group (n = 47) according to the random number table method. The control group was treated with the GDP chemotherapy regimen， and the study group was treated with Rituximab Injection on this basis. The clinical efficacy after treatment， immune function indexes [immunoglobulin (Ig) A， IgM， IgG and the body fluid complement C3， C4]， tumor markers [thymine deoxy kinase (TK-1)， vascular endothelial growth factor (VEGF)] before and after treatment were compared in the two groups. The adverse reactions of the two groups during treatment were observed. Results After treatment， the total effective rate of the study group was significantly higher than the control group (P < 0.05). IgA， IgM， IgG， C3， C4 of the two groups after treatment were lower than those before treatment， C3 and C4 of the study group were lower than those of the control group， the differences were statistically significant (P < 0.05)； there was no significant difference in IgA， IgM， IgG between the two groups after treatment (P > 0.05). After treatment， TK-1 and VEGF of the two groups were lower than those before treatment， which of the study group were lower than those of the control group， the differences were statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P > 0.05). Conclusion Rituximab Injection combined with GDP chemotherapy in the treatment of NHL has a certain effect and can effectively protect the immune functions of the patients， significantly decrease the levels of serum TK-1 and VEGF， and does not increase the incidence of adverse reactions. It has certain clinical application value., http://www.100md.com(盛薇薇 邵钰)
[关键词] 利妥昔单抗；GDP化疗；非霍奇金淋巴瘤；免疫功能
[中图分类号] R733 [文献标识码] A [文章编号] 1673-7210(2018)12(b)-0098-04
[Abstract] Objective To explore the effect of Rituximab Injection combined with GDP chemotherapy on the efficacy and immune function of patients with non Hodgkin lymphoma (NHL). Methods Ninety-three NHL patients admitted to Taikang Xianlin Drum Tower Hospital of Nanjing City in Jiangsu Province from May 2014 to December 2017 were selected as the research subjects. The patients were divided into control group (n = 46) and study group (n = 47) according to the random number table method. The control group was treated with the GDP chemotherapy regimen， and the study group was treated with Rituximab Injection on this basis. The clinical efficacy after treatment， immune function indexes [immunoglobulin (Ig) A， IgM， IgG and the body fluid complement C3， C4]， tumor markers [thymine deoxy kinase (TK-1)， vascular endothelial growth factor (VEGF)] before and after treatment were compared in the two groups. The adverse reactions of the two groups during treatment were observed. Results After treatment， the total effective rate of the study group was significantly higher than the control group (P < 0.05). IgA， IgM， IgG， C3， C4 of the two groups after treatment were lower than those before treatment， C3 and C4 of the study group were lower than those of the control group， the differences were statistically significant (P < 0.05)； there was no significant difference in IgA， IgM， IgG between the two groups after treatment (P > 0.05). After treatment， TK-1 and VEGF of the two groups were lower than those before treatment， which of the study group were lower than those of the control group， the differences were statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P > 0.05). Conclusion Rituximab Injection combined with GDP chemotherapy in the treatment of NHL has a certain effect and can effectively protect the immune functions of the patients， significantly decrease the levels of serum TK-1 and VEGF， and does not increase the incidence of adverse reactions. It has certain clinical application value., http://www.100md.com(盛薇薇 邵钰)